Laparoscopic endoscopic cooperative surgery for the duodenal neuroendocrine tumor

ISRCTN ISRCTN38499247
DOI https://doi.org/10.1186/ISRCTN38499247
Submission date
10/04/2023
Registration date
15/04/2023
Last edited
12/04/2023
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Duodenal neuroendocrine tumors (D-NETs) are uncommon tumors that start in the nerves and gland cells of the first part of the small intestine. Laparoscopic and endoscopic cooperative surgery (LECS) is a promising approach for treating gastrointestinal (digestive system) tumors. This study aims to evaluate the feasibility and safety of LECS for D-NETs.

Who can participate?
Patients aged 20-80 years with duodenal neuroendocrine tumors

What does the study involve?
Patients with D-NET who had LECS have their medical records retrospectively evaluated. A CT scan and upper gastrointestinal endoscopy with biopsy are required for routine evaluation of the disease and detection of probable metastases (secondary tumors). After the initial diagnosis, endoscopic ultrasonography (EUS) is used to evaluate the invasive depth and exclude local lymph node metastases. Functional imaging, like somatostatin receptor scintigraphy, is used when there is an abnormality in conventional imaging.
Generally, LECS is performed through collaboration between the surgical team and endoscopists. The same skilled endoscopist (Dr Gui-Qi Wang) performs all endoscopic procedures with endoscopic full-thickness resection.

What are the possible benefits and risks of participating?
The benefits and risks are the same as the usual surgery

Where is the study run from?
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (China)

When is the study starting and how long is it expected to run for?
September 2018 to January 2027

Who is funding the study?
1. Sanming Project of Medicine in Shenzhen (China)
2. Chinese Academy of Medical Sciences (China)

Who is the main contact?
Dr Hoi-Ioi Ng, 15811329134@139.com

Contact information

Dr Hoi-Ioi Ng
Principal Investigator

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing
100021
China

Phone +86 (0)15811329134
Email 15811329134@139.com

Study information

Study designNon-randomized study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Community
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleLaparoscopic endoscopic cooperative surgery for the duodenal neuroendocrine tumor
Study objectivesLaparoscopic and endoscopic cooperative surgery (LECS) is feasible for duodenal neuroendocrine tumor (D-NET)
Ethics approval(s)Approved 03/11/2021, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National GCP Center for Anticancer Drugs, The Independent Ethics Committee (No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China; +86 (0)8778 8495; cancergcp@163.com), ref: 21-458/3129
Health condition(s) or problem(s) studiedDuodenal neuroendocrine tumor
InterventionPatients with D-NET who had LECS had their medical records retrospectively evaluated. Enhanced computed tomography (CT) scan and upper gastrointestinal (GI) endoscopy with biopsy were required for routine evaluation of the disease and detection of probable metastases. After the initial diagnosis, endoscopic ultrasonography (EUS) was indicated to evaluate the invasive depth and exclude local lymph node metastasis (LNM). Functional imaging, like somatostatin receptor scintigraphy (for example, positron emission tomography (PET)/CT with 68Ga-DOTA-peptides), would be indicated when there is an abnormal in conventional imaging. The LECS criteria included the following: 1) Histological confirmation of NETs; 2) tumor diameter no greater than 10 mm; 3) confined to the mucosal or submucosal layer on EUS; 4) absence of regional or distant lymph node metastases on imaging; 5) non-ampullary NETs.

Endoscopic procedure
Generally, LECS was performed through collaboration between the surgical team and endoscopists. The same skilled endoscopist (Dr Gui-Qi Wang) performed all endoscopic procedures with endoscopic full-thickness resection (EFTR). The details of EFTR have been discussed in previous research.

Surgical procedure
The patient was positioned with legs apart in a modified Trendelenburg position. Five trocars were put in a V shape. As an observation port, a 10-mm trocar was placed through the umbilical cord. The pneumoperitoneum was created by the insufflation of carbon dioxide to an abdominal pressure of 12 mmHg. Trocars measuring 5 mm were inserted into the upper right, upper left, and left abdominal lateral regions, respectively. As the main port, a 12-mm trocar was placed in the right lateral abdominal region. Kocher mobilization was undertaken, if necessary, to expose the second portion of the duodenum. This procedure made it easier to have a clear visualization for suturing. The lesion was collected in a plastic bag and extracted through the main port. The defect was manually closed using a 15-cm barbed running suture (V-LOCTM 180 Absorbable Wound Closure Device, Covidien, Mansfield, MA). Under the surveillance of the surgeon and endoscopist, the absence of air leakage and stenosis was finally confirmed. A drainage catheter was positioned near the duodenal incision. A feeding tube was usually inserted through the closed wound in case of duodenal stasis. On the third postoperative day, duodenal patency was evaluated by upper gastrointestinal imaging.
Intervention typeProcedure/Surgery
Primary outcome measureEn bloc resection rate measured using pathology at 1 month after surgery
Secondary outcome measures1. Absence of involvement of the lateral or vertical margins measured using pathology at 1 month after surgery
2. Absence of lymphovascular invasion measured using pathology at 1 month after surgery
Overall study start date01/09/2018
Completion date01/01/2027

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit20 Years
Upper age limit80 Years
SexBoth
Target number of participants30
Key inclusion criteria1. Biopsy showed NET in the duodenum
2. Aged 20-80 years old
3. Agree to have LECS
Key exclusion criteriaLost to follow-up
Date of first enrolment07/09/2018
Date of final enrolment01/09/2026

Locations

Countries of recruitment

  • China

Study participating centre

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
PanJiaYuanNanLi 17#
Beijing
100021
China

Sponsor information

Chinese Academy of Medical Sciences & Peking Union Medical College
University/education

PanJiaYuanNanLi 17#
Beijing
100021
China

Phone +86 (0)8778 8547
Email zlyygbgl@163.com
Website http://www.cicams.ac.cn
ROR logo "ROR" https://ror.org/02drdmm93

Funders

Funder type

University/education

Chinese Academy of Medical Sciences
Government organisation / Local government
Alternative name(s)
CAMS
Location
China
Sanming Project of Medicine in Shenzhen
Government organisation / Local government
Alternative name(s)
'sanming' project of medicine in Shenzhen, Sanming Project of Medicine in Shenzhen, San-Ming Project of Medicine in Shenzhen, Sanming Project of Medicine in Shenzen Municipal
Location
China

Results and Publications

Intention to publish date01/09/2027
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryPublished as a supplement to the results publication
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe dataset generated and analysed during the current study will be published as a supplement to the results publication.

Editorial Notes

12/04/2023: Trial's existence confirmed by the Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College.